All Posts

robotics-in-surgery
Robotics in Surgery: Has the Revolution Arrived?

With the onset of the fourth industrial revolution in the twenty-first century, a new branch emerged: Robotics. Robotics is the amalgam of computer science and engineering to make programmable machines that aim to assist humans in their tasks and produce results with minimum error. From space science to healthcare ...

Find More

Orthopedic Implants Market Growth Analysis and Key Companies
Orthopedic Implants: Evaluating the Market Potential of the Unparalleled & Life-Saving Equipment

Musculoskeletal disorders are one of the most common disorders affecting a significant proportion of the population worldwide. They can have severe long-term pain, high levels of physical disability, various types of psychological distress, and reduced quality of life. As per the WHO (2022), musculoskeletal conditi...

Find More

Pharma News and Updates for AbbVie, Arrowhead Pharma, Novartis, FORE Biotherapeutics, Ellipses Pharma, Karuna Therapeutics
AbbVie Announces Results of Study Evaluating SKYRIZI; FDA Fast Track Designation to Arrowhead’s ARO-APOC3; FDA Approves Dabrafenib Plus Trametinib for BRAF V600E–Mutated Low-Grade Glioma; FDA Grants ODD to Novel BRAF Inhibitor for Brain/CNS Malignancies; EP0042 Wins FDA Orphan Drug Status; Karuna Therapeutics Announces Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia

AbbVie Announces Positive Results of Study Evaluating SKYRIZI in Plaque Psoriasis Patients AbbVie announced new 52-week data from an open-label, a single-arm study demonstrating improved plaque psoriasis signs and symptoms in a difficult-to-treat patient population who received SKYRIZI® (risankizumab), an IL-23 ...

Find More

MedTech News and Update for Sight Sciences, HeartBeam, LIVMOR, Occlutech, PADM Medical, Kardium, LivaNova
Sight Sciences’s Ergo-Series of the OMNI® Surgical System; HeartBeam to Acquire LIVMOR’s Assets; Occlutech Atrial Flow Regulator (FROST-HF) Study Updates; US FDA 510(k) Clearance for PADM Medical’s PRECISION ECO; Kardium ‘s Pulsed-Field Ablation Study; US FDA 510(k) Clearance for LivaNova’s Essenz Heart-Lung Machine

Ergo-Series of the OMNI® Surgical System Launched by Sight Sciences On March 9, 2023, Sight Sciences, Inc., an eyecare technology company focused on developing and commercializing innovative technology, providing solutions for transforming care and improving patients' lives, announced the launch of the Ergo-Seri...

Find More

emerging-therapies-for-obesity-treatment
Obesity Treatment: Which Pipeline Therapy Will Revolutionize the Therapeutics Segment?

Obesity is the second most common cause of preventable death, associated with the risk of developing inflammatory components, directly and indirectly, related to cardiovascular disease, diabetes mellitus, respiratory problems, psychological issues, hypertension, obstructive sleep apnea, cancer, and hyperlipidemia. ...

Find More

immune-oncology-therapeutics-for-cancer-treatment
Immuno-Oncology (I-O) Therapeutics: The Key to Future Cancer Treatment

Oncology has become a growing area of interest for pharmaceutical companies over the years. With a significant increase in R&D and healthcare spending worldwide, companies ranging from large pharmaceutical conglomerates to smaller biotech organizations are frantically attempting to capitalize on lucrative marke...

Find More

Artificial Intelligence in Drug Commercialization Market Outlook, Key Companies, and Products
Utilization of Artificial Intelligence for Drug Commercialization

The amount of health and "omics-related data" produced and stored has increased exponentially during the last few decades. In clinical trials, patient data can be gathered in real-time and examined using various artificial intelligence (AI) techniques; mobile devices can also be utilized to enhance certain facets o...

Find More

Pharma news and updates for Roche, Acadia, Shorla Oncology, Calliditas, Mesoblast, Sanofi, Provention Bio
Sanofi to Acquire Provention Bio; USFDA Committee Votes in Favor Roche’s Polivy; FDA to Review Mesoblast’s GvHD Drug; FDA Approves Acadia’s Daybue ; FDA Approves Nelarabine Injection; Calliditas’s Nefecon Trial Reuslt in IgA Nephropathy

Sanofi to Acquire Provention Bio for USD 2.9 Billion Sanofi and Provention Bio, Inc., a publicly traded biopharmaceutical company based in the United States focused on intercepting and preventing immune-mediated diseases such as type 1 diabetes (T1D), have agreed to acquire Provention Bio, Inc. for $25.00 per sh...

Find More

cancer-biomarkers-for-cancer-treatment
Cancer Biomarkers: Improving Treatment and Detection

Cancer is the second leading cause of death worldwide, after ischemic heart disease. There are approximately 200 different types of cancer, with lung, prostate, colorectal, stomach, and liver cancer being the most common in men and breast, colorectal, lung, cervical, and thyroid cancer being the most common in wome...

Find More

competitive-analysis-of-celmods-and-revlimid
CELMoDs – A Worthy Successor to REVLIMID?

Over the years, REVLIMID has become an integral weapon in the cancer therapeutics’ armory. This odyssey of REVLIMID in the multiple myeloma segment began in 2005, when it was approved by the US FDA for the treatment of adult patients with multiple myeloma, in combination with dexamethasone.  As the wise say...

Find More